Abstract
Today, the ‘obesity pandemic’ is one of the biggest health issues around the world. Melanin-concentrating hormone (MCH), a hypothalamic neuropeptide, is one of the most potent, central stimulators of feeding and it also attenuates energy expenditure. Inhibitions of the MCH receptor, the melanin-concentrating hormone receptor-1 (MCHR1), has attracted considerable attention as a potential anti-obesity drug, during the last decade. Now, there are a large number of MCHR1 antagonists, pharmacological tools and clinical drug candidates that can provide clues to develop new structures with high potency and good pharmacokinetic profile. The function of MCHR1 in energy homeostasis, obesity, metabolic syndrome, mood disorders and inflammatory bowel disease is discussed. Relevant clinical trials and patent background information of the MCHR1 antagonists over the last 4 years are also reviewed.
Keywords: Clinical trial, inflammatory bowel disease, melanin-concentrating hormone receptor-1 (MCHR1), mood disorder, obesity, patents.
Recent Patents on CNS Drug Discovery (Discontinued)
Title:Recent Patents on Novel MCH1 Receptor Antagonists as Potential Anti-Obesity Drugs
Volume: 9 Issue: 2
Author(s): Katalin K. Szalai, Gyula Beke, Janos Eles, Tamas Kitka, Peter Kovacs, Jozsef Nagy, Sandor Farkas and Andras Boros
Affiliation:
Keywords: Clinical trial, inflammatory bowel disease, melanin-concentrating hormone receptor-1 (MCHR1), mood disorder, obesity, patents.
Abstract: Today, the ‘obesity pandemic’ is one of the biggest health issues around the world. Melanin-concentrating hormone (MCH), a hypothalamic neuropeptide, is one of the most potent, central stimulators of feeding and it also attenuates energy expenditure. Inhibitions of the MCH receptor, the melanin-concentrating hormone receptor-1 (MCHR1), has attracted considerable attention as a potential anti-obesity drug, during the last decade. Now, there are a large number of MCHR1 antagonists, pharmacological tools and clinical drug candidates that can provide clues to develop new structures with high potency and good pharmacokinetic profile. The function of MCHR1 in energy homeostasis, obesity, metabolic syndrome, mood disorders and inflammatory bowel disease is discussed. Relevant clinical trials and patent background information of the MCHR1 antagonists over the last 4 years are also reviewed.
Export Options
About this article
Cite this article as:
Szalai K. Katalin, Beke Gyula, Eles Janos, Kitka Tamas, Kovacs Peter, Nagy Jozsef, Farkas Sandor and Boros Andras, Recent Patents on Novel MCH1 Receptor Antagonists as Potential Anti-Obesity Drugs, Recent Patents on CNS Drug Discovery (Discontinued) 2014; 9 (2) . https://dx.doi.org/10.2174/1574889809666140613115426
DOI https://dx.doi.org/10.2174/1574889809666140613115426 |
Print ISSN 1574-8898 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3954 |
Related Books
Related Articles
-
Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews Old Age Before Cognitive Impairment
Current Alzheimer Research Brain Structural Abnormalities at the Onset of Schizophrenia and Bipolar Disorder: A Meta-analysis of Controlled Magnetic Resonance Imaging Studies
Current Pharmaceutical Design Metabolic Features of Melanoma: A Gold Mine of New Therapeutic Targets?
Current Cancer Drug Targets MDMA and Impulsivity: A Review
Current Psychiatry Reviews Why are Antidepressant Drugs Effective Smoking Cessation Aids?
Current Neuropharmacology An 8-Year Retrospective Study of Human Visceral Leishmaniasis
Current Clinical Pharmacology Effects of Acute and Chronic Treatment of Novel Psychotropic Drug, 8- (Trifluoromethyl)-1, 2, 3, 4, 5-benzopentathiepin-6-amine Hydrochloride (TC-2153), on the Behavior of Zebrafish (Danio Rerio): A Comparison with Fluoxetine
Letters in Drug Design & Discovery Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Epigenetic Control of MicroRNA Expression and Aging
Current Genomics Pituitary Microadenoma Treated with Antipsychotic Drug Aripiprazole
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Towards Optimal Heart Failure Care: Couples-Oriented Strategies to Improve Patient Adherence and Health Outcomes
Current Cardiology Reviews Processing of Amyloid Precursor Protein as a Biochemical Link Between Atherosclerosis and Alzheimers Disease
Cardiovascular & Hematological Disorders-Drug Targets The Use of Stem Cells in Regenerative Medicine for Parkinson’s and Huntington’s Diseases
Current Medicinal Chemistry Electrodeposition Techniques to Synthesize Electrocatalytic Nanomaterials for High Energetic Electrodes for Battery and Fuel Cell
Nanoscience & Nanotechnology-Asia Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment
Current Genomics Trait vs. State Markers for Schizophrenia: Identification and Characterization Through Visual Processes
Current Psychiatry Reviews Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors
Mini-Reviews in Medicinal Chemistry Hypothetical Link Between Infertility and Genetically Modified Food
Recent Patents on Food, Nutrition & Agriculture